MORRISTOWN, N.J., June 2, 2011 /PRNewswire/ -- C3i, a world leader in clinical trial support services, today announced the signing of its newest client, XBiotech, Inc. XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. C3i, a Gold level member in Oracle PartnerNetwork (OPN), will provide a full-service technical solution to support its program of promising clinical trials.
Leveraging its proprietary help desk support and end user training systems, in conjunction with Oracle's market-leading Oracle Clinical and Oracle Remote Data Capture clinical data management system, C3i provides a turnkey solution to meet the needs of scientifically focused organizations like XBiotech.
C3i will provide XBiotech with global site training and support services to enable participating clinical sites to rapidly become proficient in the use of Oracle Remote Data Capture, a leading data capture solution that allows clinical site personnel to collect study patients' data at the investigator site and facilitates higher quality data.
XBiotech required a world-class data management system on which to build and manage its clinical trials and the support of consultants with the technical expertise and industry experience necessary to get their trials up and running quickly.
"C3i's comprehensive services combined with Oracle Health Sciences solutions provide us with the opportunity to manage our clinical data in a top-tier system, that is hosted and operated with expertise and experience," said Michael Stecher M.D., XBiotech's Medical Director.
"We are excited to welcome a growing company like XBiotech as a client. We believe they exemplify the still emerging potential of the important biotech industry." added Joel Morse, C3i's CEO. "Our business process outsourcing solution is well-suited to XBiotech's current data management and IT requirements, and provides them with a flexible model to accommodate their growth."
Tyler Prince, group vice president, North America Sales, Applications and Public Sector Alliances & Channels, Oracle pointed out that "C3i's full range of tailored services illustrate the value that Oracle partners bring to our joint customers."
About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations in North America, Europe, India and China. Their 1200 employees provide systems implementation, technology training, multi-lingual help desk, hardware provisioning, and break/fix, asset management, and user/application administration services for pharmaceutical sales and clinical professionals worldwide. To learn more, visit www.c3i-inc.com.
C3i is a Gold-level member of Oracle® PartnerNetwork.
About XBiotech: XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. To learn more, visit www.xbiotech.com
Oracle and Java are registered trademarks of Oracle and/or its affiliates.
Copyright©2010 PR Newswire.
All rights reserved